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Summary
Chronic thromboembolic pulmonary hypertension 
(CTEPH) is a rare and potentially fatal disease which 
occasionally occurs as a complication of acute pulmo­
nary embolism. The mechanisms leading to failure of 
thrombus resolution are not completely understood 
with only some risk factors identified. Vascular altera­
tions are present in the large and small vessel compart­
ment. Signs and symptoms of CTEPH are nonspecific, 
rendering diagnosis challenging. A VQ scan followed by 
computed tomography, magnetic resonance or conven­
tional pulmonary angiography is mandatory to confirm 
diagnosis and assess operability by a multidisciplinary 
team. Pulmonary endarterectomy remains the treat­
ment of choice in operable patients and results in sig­
nificantly improved haemodynamics and functional ca­
pacity.
In inoperable patients medical treatment is well 
defined, and mainly includes the recently introduced 
pharmacological substances with impact on haemo­
dynamics and functional performance. 
Key words:  chronic thromboembolic pulmonary hy-
pertension
Introduction
Chronic thromboembolic pulmonary hypertension 
(CTEPH) is defined as symptomatic PH with persis­
tent pulmonary perfusion defects despite 3–6 months 
of adequate anticoagulation [1]. CTEPH is a rare com­
plication following an acute pulmonary embolism (PE) 
with an incidence reported up to 5% [2]. However, 
 previous PE is not necessary for CTEPH diagnosis. Ob­
struction is composed of a central mechanical obstruc­
tion with potential for resection and a small vessel 
component of variable importance. In operable pa­
tients, CTEPH might be curable by surgical pulmonary 
endarterectomy [3]. In surgically inaccessible patients, 
medical therapy improves exercise capacity and 
haemodynamics [4]. CTEPH has 
been recently comprehensively 
summarised by the last WHO con­
ference on PH held in Nice [5]. We 
review CTEPH from epidemiology 
and pathogenesis to clinical presen­
tation, diagnosis and treatment.
Epidemiology
The prevalence of CTEPH varies between 3 to 30/1 mil­
lion in the population [6]. Among newly diagnosed 
cases only 60% to 75% have a history of acute PE. Thus, 
pathophysiological mechanisms other than PE might 
lead to CTEPH. The incidence of CTEPH following 
acute PE is unknown and varies greatly according to 
the setting. Numbers from 0.6% to 8.8% have been re­
ported [2, 7, 8]. In one study, the cumulative incidence 
of CTEPH was 1% at 6 months, 3.1% at 1 year and 3.8% 
at 2 years after acute PE [2]. Interestingly, no new 
CTEPH cases were noted after 2 years in the follow­up 
period up to 10 years. 
Predictors for CTEPH after acute PE are young 
age, large perfusion defects, multiple PE episodes and 
elevated pulmonary pressure at the time of PE, espe­
cially a right ventricular systolic pressure ≥50 mm Hg 
[9]. Additional risk factors for CTEPH include splenec­
tomy, thyroid replacement therapy, infected pacemaker 
lines, infected tunnelled catheter systems, chronic os­
teomyelitis, a history of malignancy, ventriculoatrial 
shunt, antiphospholipid antibodies/lupus anticoagu­
lant, inflammatory bowel disease, HLA polymorphism, 
non­O blood groups and fibrinogen variants resistant 
to fibrinolysis [10, 11].
The development of CTEPH due to prothrombotic 
states is supported by the following observations: a 
strong association with venous thromboembolism and 
high levels of factor VIII [12]. Interestingly, even after 
a successful surgical pulmonary endarterectomy 
(PEA), the factor VIII level remains elevated [13]. In 
contrast, Factor V Leiden mutations, protein C and S 
deficiency and antithrombin III were not associated 
with CTEPH [14, 15].
Haemodynamic parameters at CTEPH diagnosis 
predict survival. A mean pulmonary arterial pressure 
(mPAP) of ≥50 mm Hg is associated with a 2­year mor­
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Within the small vessel compartment, changes 
similar to pulmonary arterial hypertension (PAH) are 
observed in CTEPH [12]. Abnormal endothelial func­
tion, excessive proliferation of smooth muscle cells, 
 migration of fibroblasts and inhibition of apoptosis in 
vascular smooth muscle cells lead to endothelial dys­
function, vascular remodelling and microthrombosis 
[25]. As in PAH, a persistent vasoconstrictive state, 
characterised by high levels of plasma endothelin­1 
and overexpression of type B endothelin receptors, may 
be present in CTEPH patients [26]. 
The combination of proximal thrombus occlusion 
and vascular remodelling in nonoccluded vessels leads 
to elevated pulmonary vascular pressure and resist­
ance (PVR) with consecutive right heart hypertrophy 
and progressive right heart failure.
Clinical presentation
The main symptoms associated with CTEPH are non­
specific, such as progressive dyspnoea and exercise 
 intolerance. They are often primarily considered to be 
associated to other states, like obstructive lung disease, 
deconditioning and obesity [5]. Haemodynamically, the 
cardiac output is limited by the high PVR. Minute ven­
tilation is augmented due to an increase of dead space 
[27]. Considering that 35% of patients do not have a 
history of acute PE, the diagnosis is challenging. In 
clinical examination, a fixed split or accentuated pul­
monic component of the S2 are common findings. Exer­
tality of >80%, a mPAP >30 mm Hg with a 3­year mor­
tality of 90% [16]. 
Echocardiography screening in patients after high­ 
and intermediate risk acute PE should be considered 
up to 2 years after the acute event [17]. In order to 
 allocate resources to the patient who will profit most, it 
is suggested to focus surveillance programmes after 
acute PE on patients with mainly central vessel embo­
lisation and evidence of right ventricle dysfunction [18]. 
Pathogenesis
In CTEPH patients, pulmonary vascular changes are 
observed at two levels. 
The large vessel compartment is mainly affected by 
obstruction and remodelling of the pulmonary vascular 
bed by fibrous material, which may completely occlude 
or obstruct the lumen by webs and bands of scaring 
thrombus [19, 20]. The normal pathophysiological reac­
tion, driven by vascular endothelial growth factor and 
basic fibroblastic growth factor [21], involves an en­
dothelial activation of the affected vessel with penetra­
tion of the thrombus in order to finally form vascular 
channels within the occluding clot [22]. In CTEPH 
 patients, a combination of inappropriate angiogenesis 
[23] and inflammatory state (presence of proinflamma­
tory cytokine macrophage chemoattractant protein­1 
[24] impairs the thrombus resolution. Abnormal fibrin­
ogen types, failure to cleave fibrinogen by plasminogen 
[12] and fibrotic changes are also involved. 
Figure 1
CTEPH diagnostic algorithm.
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tional syncope and signs of RV failure are found in pro­
gressive disease. If a right­to­left shunt is present 
through a patent foramen ovale, cyanosis might be ob­
served. 
CTEPH diagnosis
A ventilation perfusion (VQ) scan is the screening goal 
of choice to distinguish CTEPH from PH. With 96% 
sensitivity, a normal VQ scan allows CTEPH to be 
ruled out. VQ scans only require a limited radiation 
dose, do not depend on intravenous contrast agents and 
are of low cost. Despite these advantages, VQ scans 
seem to be underutilised in the evaluation of CTEPH. 
In one study, 43% of patients with precapillary PH did 
not have a VQ scan according to a quality report and 
thus might have been misclassified [28].
In case of an abnormal VQ scan, pulmonary digital 
subtraction angiography is still considered as the 
golden standard to diagnose CTEPH. Pulmonary 
angio graphy accurately depicts the extension of the 
thromboembolic disease and, together with pulmonary 
haemodynamics, allows evaluation of operability for 
pulmonary endarterectomy (PEA).
Computed tomography pulmonary angiogram 
(CTPA) is performed in many centres to diagnose 
CTEPH in addition to VQ scans and pulmonary angio­
graphy. Some specialist teams even rely on this tech­
nique to base their decision on surgical accessibility of 
CTEPH. CTPA has the advantage of providing addi­
tional data on lung parenchyma, mediastinal lymph 
nodes, bronchial arteries and differential diagnosis. 
However, the diagnostic accuracy of this imaging tech­
nique depends on the experience of the radiologist and 
other interpreters, as various pathologies might present 
similarly as CTEPH, such as pulmonary artery sar­
coma, tumour emboli into the pulmonary artery (from 
renal, thyroid, testicular and uterine cancer), embolisa­
tion of hydatic cysts of the liver, pulmonary arteriitis 
(Takayashu, Behçet) or fibrous mediastinitis. Proximal 
lining thrombi associated with pulmonary  arterial hy­
pertension can also mimic chronic thromboembolic dis­
ease. On the other hand, distal disease in segmental or 
subsegmental arteries may be missed in CTPA. How­
ever, in the  latest generation of CT scanners, the resolu­
tion of the images allows a better evaluation of vascular 
wall  thickness and surrounding structures. In compari­
son to conventional angiography, no need for catheter 
access makes CTPA more comfortable. Emerging tech­
niques, such as dual energy CT and lung perfusion MRI 
are additional promising tools in the diagnosis and op­
erability assessment of CTEPH. It is important to state 
that both pulmonary angiography and CTPA should be 
performed and interpreted in experienced PH­centres 
with access to surgical pulmonary endarterectomy. 
In summary, according to the NICE PH conference 
2013:
– VQ scan is recommended as screening tool for 
chronic thromboembolic disease in all patients 
with no obvious reason for precapillary PH.
– Pulmonary angiography remains the gold stand­
ard for confirmation of chronic thromboembolic 
disease and evaluation of operability.
– High­quality multidetector CTPA may be a suit­
able alternative to pulmonary angiography in cen­
tres with experience in CTEPH.
Surgical therapy
Pulmonary endarterectomy (PEA) has transformed 
CTEPH from a fatal disease to a potentially curable 
form of PH. PEA is classically performed via a median 
sternotomy to have access to both lungs and to install 
a cardiopulmonary bypass. Cooling to 20 °C allows 
deep hypothermic circulatory arrest (DHCA) to provide 
a clear operating field. The endarterectomy dissection 
plane should be circumferential in order to be able to 
dissect until the level of segmental and even subseg­
mental branches, a simple thrombectomy or embolec­
tomy without a true endarterectomy will not help to 
 reduce the PVR (fig. 2) [29]. In experienced centres, the 
procedure is safe with a mortality below 5% [30, 31]. 
Successful outcomes for patients undergoing PEA have 
been reported in improvement of exercise capacity, 
haemodynamics (improving PVR by up to 80%) quality 
of life and life expectancy (90% survival rate at 5 years) 
[32].
Recently, a prospective, controlled trial (PEACOG) 
showed that DHCA compared with cerebral perfusion 
during pulmonary endarterectomy surgery resulted in 
similar performance at 3 months and 1 year after 
 surgery in the DHCA group [33]. Surprisingly, cogni­
tive function was even improved after the PEA, likely 
due to the improved cardiac output. 1­year survival 
was 96%. The authors of the trial recommended DHCA 
as the best procedure, as 9 patients (from 74) had to 
cross over from antegrade cerebral perfusion to DHCA 
in order to keep the operating field clear. 
Despite favourable outcomes in most patients, 
there are two major well­known complications in the 
postoperative course of PEA: residual PH and reperfu­
sion lung injury [5]. Persistently elevated pulmonary 
pressure often occurs in combination with reperfusion 
lung injury. The emerging and improved technology of 
extracorporeal membrane oxygenation offers good 
 salvage solution for both situations: venoarterial extra­
corporeal membrane oxygenation (ECMO) is used in 
case of haemodynamic instability. The right ventricle 
can be offloaded as well as PA pressures being  reduced 
and therefore cardiac output and gas exchange are im­
proved. In case of reperfusion injury alone, conserva­
tive therapy or veno­venous ECMO can be used [34]. 
Survival rates of these PEA­complications up to 57% 
are reported.
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Since 2001, reports mainly from Japan emerged 
about innovative percutaneous pulmonary angioplasty 
done in patients which were noneligible for surgery 
due to comorbidities [35–39]. Multiple angioplasty pro­
cedures were necessary to achieve a significant reduc­
tion of the pulmonary vascular resistance and the stud­
ies were neither randomised nor controlled. Neverthe­
less, haemodynamic improvements were impressive as 
well as improvements in the 6­minute walking dis­
tance and WHO functional class, and the procedure 
was safe, even in elderly patients [36]. Thus, this novel 
treatment option might be considered in CTEPH­pa­
tients who are not eligible for surgery due to comorbid­
ities. Despite these promising reports, further con­
trolled trials and long­term data will be required in 
 order to define the role of pulmonary angioplasty in the 
CTEPH­treatment algorithm and to address risks such 
as bleeding or vessel rupture and complications such as 
the occurrence of restenosis.
In conclusion, CTEPH is a surgically curable dis­
ease for some patients affected and we therefore under­
line the importance of the operability assessment 
through a multidisciplinary CTEPH specialised team.
Medical therapy 
Lifelong anticoagulation is the foundation of treatment 
in all patients with CTEPH regardless of therapy and 
interventions [5]. Mostly, vitamin­K antagonists are 
used in this indication. Although there are no trials 
specifically performed in CTEPH, it is reasonable to as­
sume that other anticoagulants such as heparines or 
direct inhibitors of FXa (e.g. rivaroxaban, apixaban) or 
thrombin (dabigatran) are similarly effective [40]. The 
former might more be used for short­time bridging (e.g. 
perioperatively) the latters have the advantage that 
they can be given in fixed daily doses, do not need mon­
itoring, have less drug­drug and drug­food interactions 
and have demonstrated favourable bleeding­risk­to­
benefit ratio as demonstrated in several trials in 
 patients with venous thromboembolism [40, 41]. 
CTEPH patients are considered to be inoperable in 
up to 50% of cases. Reasons include distal disease, 
 comorbidities (COPD, severe left ventricular dysfunc­
tion) and excessively high PVR [19]. For patients 
 considered unsuitable for PEA or with postoperative 
persistent PH, pharmacological treatment with PH­
Figure 2
A  Endarterectomy of the right pulmonary artery and dissection plane. (From: Opitz I, de 
Perrot M. technique of pulmonary thromboendarterectomy. Op Techniques Thorac 
Cardiovasc Surgery. 2012;17(3):168–80. DOI: 10.1053/j.optechstcvs.2012.07.004)
B Endarterectomy specimen of the right and left pulmonary artery.
A B
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targeted therapies can be offered [5]. CTEPH and 
 pulmonary arterial hypertension (PAH) share many 
pathogenetic features [42]. Thus, medical therapy as 
used for PAH (PAH­target therapy) can be prescribed. 
Benefits of pulmonary vasodilators have been reported 
in various trials. BENEFiT was the first large RCT 
supporting medication with Bosentan in patients with 
inoperable forms of CTEPH. Bosentan given for 
6 months reduced PVR by 24% compared to placebo but 
could not improve the 6­minute walking distance [43]. 
More recently, clinically relevant primary end­
points have been reported by the large CHEST­1 trial 
assessing a new drug class, the soluble guanylate cy­
clase stimulator, Riociguat [4]. After a cautious uptitra­
tion schema in order to avoid systemic vasodilatory ef­
fects and hypotension, patients receiving Riociguat had 
a significant improvement of 46 m in the 6­minute 
walk distance and a reduction of their PVR by –31%. 
However, there was no effect on time to clinical worsen­
ing and the benefits were less pronounced among pa­
tients with persistent PH after PEA. 
In summary, PEA remains the first therapeutic 
choice for patients with surgically accessible CTEPH. 
The evaluation for PEA must be made by an experi­
enced CTEPH team. Inoperable patients with distal 
disease, comorbidities or patients with persisting 
symptomatic PH after PEA should be treated with 
medical therapy and/or considered for pulmonary an­
gioplasty. 
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